Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Bosentan Tablets USP (US RLD-Tracleer Tablets), 62.5 mg and 125 mg and Trientine Hydrochloride Capsules USP (US RLD-Syprine Capsules), 250 mg.
Both the products will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. Bosentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). Trientine is used to treat this inherited condition in people who cannot take penicillamine.
The group now has 265 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
